Cargando…

Role of uromodulin and complement activation in the progression of kidney disease

Uromodulin (UMOD) is a glycoprotein that is selectively expressed on the epithelial cells of the thick ascending limb of Henle's loop and the early distal renal tubule. The present study aimed to investigate whether UMOD was associated with complement activation in patients with renal diseases....

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Fei, Liu, Maojing, Pei, Fei, Yu, Li, Yang, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527566/
https://www.ncbi.nlm.nih.gov/pubmed/34691256
http://dx.doi.org/10.3892/ol.2021.13090
_version_ 1784586093313654784
author Shen, Fei
Liu, Maojing
Pei, Fei
Yu, Li
Yang, Xiangdong
author_facet Shen, Fei
Liu, Maojing
Pei, Fei
Yu, Li
Yang, Xiangdong
author_sort Shen, Fei
collection PubMed
description Uromodulin (UMOD) is a glycoprotein that is selectively expressed on the epithelial cells of the thick ascending limb of Henle's loop and the early distal renal tubule. The present study aimed to investigate whether UMOD was associated with complement activation in patients with renal diseases. In addition, its biological function was examined in vitro. The expression levels of UMOD and complement components, including C1q, C3, C4 and C3a, and membrane attack complex (MAC) in the plasma of patients with IgA nephropathy (IgAN; n=58) and lupus nephritis (LN; n=36) were detected using ELISA, which was used to determine the association between UMOD expression and complement components. In addition, a simulated hypoxia-reoxygenation (H/R) model was used to stimulate UMOD expression in mouse inner medullary collecting duct cells. Additionally, the association between UMOD expression and complement components C1q and C3d at the cellular level was identified using western blotting and immunofluorescence, respectively. It was revealed that the plasma UMOD concentration was significantly decreased in patients with IgAN and LN compared with in healthy controls, and the levels of C3a and MAC were significantly increased in the plasma of patients with IgAN and LN. Furthermore, the plasma levels of C1q, C3 and C4 in patients with LN, but not in patients with IgAN, were significantly decreased compared with in healthy controls. The plasma levels of UMOD were negatively correlated with the plasma C3a and MAC concentrations. However, the plasma levels of UMOD were significantly and positively correlated with the plasma C1q concentration, but not with that of C3 and C4. It was identified that UMOD expression started to increase after 1 h of simulated H/R, and continued to increase at 6 and 12 h. In addition, cells with lower UMOD expression had higher C3d expression in vitro. Collectively, the present results suggested that UMOD was associated with severe complement activation and may be involved in complement-mediated immune protection by inhibiting complement activation in renal disease.
format Online
Article
Text
id pubmed-8527566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-85275662021-10-22 Role of uromodulin and complement activation in the progression of kidney disease Shen, Fei Liu, Maojing Pei, Fei Yu, Li Yang, Xiangdong Oncol Lett Articles Uromodulin (UMOD) is a glycoprotein that is selectively expressed on the epithelial cells of the thick ascending limb of Henle's loop and the early distal renal tubule. The present study aimed to investigate whether UMOD was associated with complement activation in patients with renal diseases. In addition, its biological function was examined in vitro. The expression levels of UMOD and complement components, including C1q, C3, C4 and C3a, and membrane attack complex (MAC) in the plasma of patients with IgA nephropathy (IgAN; n=58) and lupus nephritis (LN; n=36) were detected using ELISA, which was used to determine the association between UMOD expression and complement components. In addition, a simulated hypoxia-reoxygenation (H/R) model was used to stimulate UMOD expression in mouse inner medullary collecting duct cells. Additionally, the association between UMOD expression and complement components C1q and C3d at the cellular level was identified using western blotting and immunofluorescence, respectively. It was revealed that the plasma UMOD concentration was significantly decreased in patients with IgAN and LN compared with in healthy controls, and the levels of C3a and MAC were significantly increased in the plasma of patients with IgAN and LN. Furthermore, the plasma levels of C1q, C3 and C4 in patients with LN, but not in patients with IgAN, were significantly decreased compared with in healthy controls. The plasma levels of UMOD were negatively correlated with the plasma C3a and MAC concentrations. However, the plasma levels of UMOD were significantly and positively correlated with the plasma C1q concentration, but not with that of C3 and C4. It was identified that UMOD expression started to increase after 1 h of simulated H/R, and continued to increase at 6 and 12 h. In addition, cells with lower UMOD expression had higher C3d expression in vitro. Collectively, the present results suggested that UMOD was associated with severe complement activation and may be involved in complement-mediated immune protection by inhibiting complement activation in renal disease. D.A. Spandidos 2021-12 2021-10-13 /pmc/articles/PMC8527566/ /pubmed/34691256 http://dx.doi.org/10.3892/ol.2021.13090 Text en Copyright: © Shen et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Shen, Fei
Liu, Maojing
Pei, Fei
Yu, Li
Yang, Xiangdong
Role of uromodulin and complement activation in the progression of kidney disease
title Role of uromodulin and complement activation in the progression of kidney disease
title_full Role of uromodulin and complement activation in the progression of kidney disease
title_fullStr Role of uromodulin and complement activation in the progression of kidney disease
title_full_unstemmed Role of uromodulin and complement activation in the progression of kidney disease
title_short Role of uromodulin and complement activation in the progression of kidney disease
title_sort role of uromodulin and complement activation in the progression of kidney disease
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527566/
https://www.ncbi.nlm.nih.gov/pubmed/34691256
http://dx.doi.org/10.3892/ol.2021.13090
work_keys_str_mv AT shenfei roleofuromodulinandcomplementactivationintheprogressionofkidneydisease
AT liumaojing roleofuromodulinandcomplementactivationintheprogressionofkidneydisease
AT peifei roleofuromodulinandcomplementactivationintheprogressionofkidneydisease
AT yuli roleofuromodulinandcomplementactivationintheprogressionofkidneydisease
AT yangxiangdong roleofuromodulinandcomplementactivationintheprogressionofkidneydisease